logo-loader
viewBard1 Life Sciences Ltd

BARD1 Life Sciences Ltd raising funds for novel cancer diagnostics

The company is developing diagnostic tests for early detection of cancer.

CancerHeadline.jpg
The technology is based on BARD1, a potent tumour suppressor

BARD1 Life Sciences Ltd (ASX:BD1) has received binding commitments to raise $1,097,325 via the issue of shares to sophisticated and professional investors at an issue price of $0.008 per share.

The company will also conduct a share purchase plan (SPP) for eligible shareholders to raise up to a further $1 million at the same issue price.

Funds raised from the placement and SPP will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

BARD1 is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer.

The company’s proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and an important tumour biomarker in cancer.

BARD1’s lead product, the BARD1 Lung Cancer Test, is a non-invasive blood test in development for early detection of lung cancer.

The company is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers.

BARD1’s research activities are currently performed under a research contract at the University of Geneva (UNIGE).

The company’s business strategy is to focus on leveraging its BARD1 Technology to develop diagnostic tests for early detection of cancer where there are clear unmet needs and product advantages.

Quick facts: Bard1 Life Sciences Ltd

Price: 0.029 AUD

ASX:BD1
Market: ASX
Market Cap: $39.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

DomaCom's Arthur Naoumidis discusses acquisition of first Rent-to-Own property

DomaCom Ltd's (ASX:DCL) Arthur Naoumidis caught up with Proactive's Andrew Scott following the news it's acquired the first property for its new, innovative Rent-to-Own product in the Melbourne suburb of Moonee Ponds. The one-bedroom apartment in the Mason Square development was acquired for...

1 day ago

2 min read